Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myelom
Vaxil Bio, a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration, for the treatment of multiple myeloma (MM).
Linear Mode
